Page 1 Thomas J. Grayden, M.D.

CURRICULUM VITAE

A.PERSONAL INFORMATION

NameThomas J. Grayden, M.D.

Business AddressU.C.IrvineCollege of Medicine

U.C.IrvineMedicalCenter

Neuropsychiatric Center

101 City Drive South

Orange, CA92868

Mailing AddressFANCOC

20768 La Paz Road Suite 731

Aliso Viejo, Ca 92656

Phone: (949) 207-3457

Fax: (949) 680-4147

Place of BirthMinneapolis, Minnesota

Citizenship U.S.A

Tax I.D.20-5026455

  1. EDUCATION

CollegeArizonaStateUniversity, B.S.,

Sept 1973 to June 1977

1001 S Mill Ave
Tempe, Arizona85281
(480) 965-4154

MedicalSchoolUniversity of Minnesota, M.D.,

Sept 1978 to June 1982

3 Morrill Hall

Minneapolis, MN55455

(612) 625-5000

InternshipUniversity of California, Davis

July 1982 to June 1983, Rotating Intern

DavisOne Shields AvenueDavis, CA95616

(530) 752-1011

ResidenciesUniversity of California, Irvine

July 1983 to June 1986

101 The City Drive South • Orange, CA92868

714.456.7890

FellowshipsUSC Institute of Psychiatry and Law

July 1986 to June 1987, Forensic Psychiatry

1975 Zonal Avenue

KAM 500

Los Angeles, CA 90089-9034

American Psychiatry Association, May 1996

LicensureCalifornia, 1983 (Certificate G-50401)

Board Certification Diplomate, American Board of Psychiatry and

Neurology, 1998, General Psychiatry

Diplomate, American Board of Psychiatry and

Neurology, 1999, Forensic Psychiatry

Diplomate, American Board of Forensic

Medicine, 1999

C.PROFESSIONAL BACKROUND

Academic Appointments

Clinical Instructor of Psychiatry

UC Irvine College of Medicine, 1986-1987

Clinical Instructor of Psychiatry

University of Southern California School of Medicine, 1986-1987

Assistant Clinical Professor of Psychiatry

UC Irvine College of Medicine, 1987-1996

Associate Clinical Professor

UC Irvine College of Medicine, 1996-2000

Clinical Professor

UC Irvine College of Medicine, 2001-current

Administrative Responsibilities

Chief Resident

Brea Neuropsychiatric Hospital, 1985-1986

Chief of Forensic Services, Department of Psychiatry

UC Irvine College of Medicine, 1987-Present

Attending Unit Director, Adult Inpatient Psychiatric Unit

UC Irvine College of Medicine, 1987-1988

Adult Unit Medical Director, CharterHospital Mission Viejo, 1990-1992

Secretary, Medical Executive Committee, CharterHospitalMission Viejo 1991

Medical Director, Partial Hospitalization Program, CPCLaguna HillsHospital 1992-1994

Chief of Staff, CPCLaguna HillsHospital, 1993

Medical Director, U.C.IrvineCollege of Medicine Outpatient Psychiatry Services, 1994-2006

Unit Attending Physician, Royale Therapeutic Residential Center, 1998- Present

Appointments

Expert Witness, Los Angeles County Superior Court Department 95, 1986-1987

Expert Witness, Orange County Superior Court, 1987-Present

Orange CountySuperior Court Expert Witness Panel, 1989-Present

California Medical Board Consulting Psychiatrist, 1989-1992

Teaching Responsibilities

Lecture on anxiety disorders to junior and senior medical students, 1989-2006

Lectures on forensic psychiatry as core curriculum to both psychiatry and interns and residents, 1988- Present

Elective psychiatry resident seminar on forensic psychiatry, 1988-Present

Supervision of interns and residents in Psychiatry Department, UC Irvine College of Medicine 1989- Present

Monthly staff in-service lectures on general psychiatry, Charter Hospital Mission Viejo, 1990-1992

Monthly staff in-service lectures on general and forensic psychiatry, CPC Laguna Hills Hospital, 1993-1994

D.RESEARCH PROTOCOLS PRINCIPLE INVESTIGATOR

1.A5361022 A 52 Week Open Label Safety Study Of Pd 0332334 In Subjects With Generalized Anxiety Disorder.

2.A1281158 A Six Week Double Blind Multicenter Palcebo Controlled Study Evaluating The Efficacy And Safety Of Flexible Doses Of Oral Ziprasidone As Add-On, Adjunctive Therapy With Lithium Valproate Or Lamotrigine In Bipolar Depression.

3.A5361018 A Phase 3 Randomized Double Blind Parallel Group 8 10 Week Placebo Controlled Fixed Dose Study Of Pd 0332334 And Paroxetine Evaluating The Efficacy And Safety Of Pd 0332334 For The Treatment Of Generalized Anxiety Disorder.

E.RESEARCH PROTOCOLS CO-INVESTIGATOR

1. Randomized, Parallel-Group Pilot Study to Evaluate the Brain Effects and Efficacy of Exelon Compared to Aricept in Patients with Alzheimer's Disease with a 12 month adjunctive Namenda® extension.

2. A Double-Blind, Phase II, Safety and Efficacy Evaluation of ONO-2506PO in Patients with Mild to Moderate Alzheimer's disease.

3. Alzheimer's Disease Neuroimaging Protocol (ADNI)

4. rA Six-Week, Randomized, Double-Blind, Multi-center, Fixed-Flexible Dose, Placebo-Controlled Study Evaluating the Efficacy and Safety of Oral Ziprasidone in Outpatients with Bipolar 1 Depression .

5. A Multicenter, Double-Blind, Flexible-Dose, 6 Month Trial Comparing the Efficacy and Safety of Asenapine With Olanzapine in Stable Subjects With Predominant, Persistent Negative Symptoms of Schizophrenia.

6. A Randomized, Double-Blind, Placebo-Controlled, Sequential Panel Study of the Safety and Tolerability of Progressively Decreasing Titration Schedules of Bifeprunox in Subjects with Either Schizophrenia or Bipolar Disorder with an Optional Open-Label 26-Week Extension.

7. A Multicenter, Randomized, Double-Blind, Fixed-Dose, Efficacy and Safety Trial of Farampator (Org 24448) (250 and 500 mg b.i.d.) vs. Placebo as Augmentation Therapy in Schizophrenic Subjects Currently Receiving Risperidone .

8. A double blind, placebo controlled, randomized, and single and multiple dose phase I study to explore the functional neuronal activity of farampator (Org 24448) by means of FDG PET, fMRI and pEEG in healthy subjects.

9. A Multicenter, Double-Blind, Flexible-Dose, 6 Month Extension Trial Comparing the Safety and Efficacy of Asenapine With Olanzapine in Subjects Who Completed Protocol A7501013.

10. A Double-Blind, 40-Week Continuation Study Evaluating the Safety of Asenapine and Olanzapine in the Treatment of Subjects with Acute Mania

11. A Randomized, Double-Blind, Parallel Group, Active-Controlled Tolerability and Safety Study of MK-3756 (SM 13496/Lurasidone) in Clinically Stable Schizophrenic Outpatients.

12. A Phase II, Double Blind, Randomized, Placebo-Controlled, Parallel-Group, Dose-Ranging Study Assessing the Efficacy and Safety of AC-3933 Tablets Twice Daily in Adults with Mild to Moderate Alzheimer’s Disease.

13. A Multicenter, Randomized, Double-Blind, Parallel-Group Fixed-Dose Study of the Effect on Weight of Bifeprunox versus Olanzapine in the Treatment of Outpatients with Schizophrenia.

14. A Multicenter, Randomized, Double-blind, Placebo-controlled, 16-Week Study of Aripiprazole Used as Dual Therapy in the Treatment of Patients with Chronic Stable Schizophrenia or Schizoaffective Disorder Demonstrating an Inadequate Response to Quetiapine or Risperidone Monotherapy.

15. A Multicenter, Randomized, Blinded, Controlled, Parallel Group Trial to Demonstrate the Efficacy of Reg Guided Pharmacotherapy Of Subjects With Treatment-Resistant Depression.

16. A Clinical Trial to Determine Striatal and Extrastriatal Dopamine D3D2-Receptor Occupancy after Multiple Oral Doses of RGH-188 in Schizophrenic Patients Using Positron Emission Tomography with the D3D2-Receptor Ligand 18F-Fallypride.

17. Self perceptions of risk study of violence UCI, Irvine This study is designed to develop a highly efficient method for assessing patients' risk of violence and self harm in the community. Although "risk assessment tools" are available, they are rarely used because they are time consuming and do not inform risk management well. This study will develop a clinically feasible and useful method for predicting your patients' self harm and violence. We will compare clinicians' judgment (i.e., current practice) with a brief computerized assessment (the COVR) and a completely novel approach that focuses on patients' self-perceptions of risk.

Principal Investigator: J.L. Skeem, Ph.D.

F.SOCIETY MEMBERSHIPS

Local

Orange CountyPsychiatry Society, 1985-Present

American Academy of Psychiatry and the Law, Southern California Chapter, 1987- Present

National

American Medical Association, 1981- Present

American Psychiatric Association, 1983- Present

American Academy of Psychiatry and the Law, 1986- Present

American Society of Clinical Psychopharmacology, 1993- Present

AmericanCollege of Forensic Examiners, 1999- Present

G.COMMITTEE MEMBERSHIPS

Bipolar Advisory Committee Eli Lilly 2004 to current

MedicalSchool Admission Interview Committee, College of Medicine, University of California, Irvine, 1988-2004

Membership and Credentials Committee, OrangeCounty Psychiatric Society, 1988-1992

Medical Executive Committee, CharterHospital Mission Viejo, 1990-1992

Bylaws Committee, CPCLaguna HillsHospital 1992

Medical Executive Committee, CPC Laguna Hills Hospital, 1993-1994

Pharmacy and Therapeutics Committee, CPC Laguna Hills Hospital, 1993-1994

Quality Management Committee Chairman, Department of Psychiatry Outpatient Services, U.C. Irvine, 1997- 2006

Credentials Committee, PacifiCare Behavioral Health, 1996- 2004

California Psychiatric Association Committee on Judicial Action, 2000-Present

Acting Head, Ad Hoe Residency Training director Committee, Department of Psychiatry, UC Irvine, 1999

Investigational Review Board, UC Irvine Medical Center, 1998-2006

H.CONSULTANTSHIPS

United States Department of Justice Federal Bureau of Prisons, 1986-1987

Los AngelesCounty Superior Court, 1986-1987

Los Angeles County Juvenile Court, 1986-1987

Los AngelesCounty Superior Court, Mental Health Division, 1986-1987

Los AngelesCounty Family Law Division, 1986-1987

Los AngelesCounty Municipal Court, 1986-1987

Los Angeles County District Attorney’s Office, 1986-1987

Los Angeles County Public defenders Office, 1986-1987

Los Angeles County Probation Department, 1986-1987

Los Angeles County Sheriff’s Department, 1986-1987

Los Angeles County Department of Mental Health, 1986-1987

Los Angeles County Department of Health Services, 1986-1987

California State Department of Parole, 1986-1987

CaliforniaStateUniversity, Fullerton, 1987-1988

Mental Health Court, Orange CountySuperior Court, 1987-Present

Royale Therapeutic Residential Center, 1988-Present

California Board of Medical Quality Assurance, 1989-1993

SaddlebackCollegeMission Viejo, Ca Student Health Clinic, 1989-1990

Community Psychiatric Centers at CPC Laguna Hills, BreaCanyon, and Santa Ana Hospitals, 1991-1994

Vertex Neuromedical Consultants, 1992

Brain Imagining Center, CaliforniaCollege of Medicine, University of California, Irvine, 1992-1998

Liver Transplant Team, UC Irvine Medical Center, 1994-2002

Central Nervous System Advisory Forum, Janssen Pharmaceutical Research

Foundation, 1999

I.AWARDS

Fellowship Award, American Psychiatric Association, 1996

Teacher of the Year award, Department of Psychiatry, UC Irvine, July 1, 1997, to June 30, 1998

Certificate of Recognition, UCI Institutional Review Board, June 2000

J.SPECIAL PRESENTATIONS

Use of positron emission tomography in Traumatic brain injury, Grayden, T.J., Lottenburg, S., Poster Session, PET and SPECT Brain Imagining Symposium, Johns Hopkins University School of Medicine, March 11, 1993.

Traumatic Brain Injury, T.J. Grayden, Grand Rounds, University of California, Irvine, MedicalCenter, August 16,1984.

K.BIBLIOGRAPHY

1.Grayden, T.J., “Medicine in the Courtroom: Issues of the Psychiatrist.” University Service News Vol. 3 2-3.1989.

2.Wolf, M.J., Grayden, T.J., Carreon, D., et al. “Efficacy of Time Limited Psychotherapy and Buspirone and Borderline Patients.” 1989 Western Psychological Association Program of Abstracts, April 1989.

3.Yin, Y., Carreon, D., Wolf, M., Grayden, T.J., Rice, R., Isenhart, R., Sandman, C., Potkin, S. “Increased Photic-Driving EEG Alpha in Depressed Patients.” 1990 Western Psychological Association Program of Abstracts, April 1990.

4.Wolf, M.J., Carreon, D., et al “Psychotherapy and Busiprone in Borderline Patients.” 143rd A.P.A New Research Program and Abstracts, May 1990.

5.Wolf, M.J., Grayden, T.J., Carreon, D., et al. “Treatment of Borderline Personality Disorder with a Serotonin 1a Agonist.” 114th A.P.A New Research Program and Abstracts, May 1991.

6.Yang, J., Grayden, T., “Patient Confidentially Even after the Patient Dies,” 2000 AmericanCollege of Forensic Examiners Annual Meeting, Program of Abstracts, October 2000.

7.Lavid, N.E., Grayden, T.J., Gottschalk, L.A., Bechtel, R.J., “Computerized analysis of Refusal Of Treatment: A Preliminary Study of the Influence Of Neuropsychiatric Traits on Judicial Decisions.” American Journal of Forensic Psychiatry, Volume 23, Issue 3, 2002.